MODERN VIEWS ON CLINICAL AND DIAGNOSTIC CRITERIA FOR PREMATURE OVARIAN FAILURE
DOI:
https://doi.org/10.17605/Keywords:
Premature ovarian failure, ovarian reserve, diagnosis of premature ovarian failure, infertility, amenorrhea, anti-mullerian hormone, follicle-stimulating hormoneAbstract
In recent times, postponing pregnancy to a later reproductive age has become a trend in the reproductive behavior of many women. The late reproductive period is considered to be the period from 40 to 45 years of age. Due to premature ovarian failure, a woman loses her reproductive potential by the age of 40, and this is a significant social problem. Women with this disease are at risk of a number of diseases associated with estrogen deficiency: impaired endothelial function, ischemic heart disease and its associated risks, a higher rate of bone fractures due to osteoporosis, decreased cognitive function, poorer quality of sexual life, and an increased risk of premature death. The purpose of this article is to systematize modern clinical diagnostic criteria for premature ovarian failure, their early detection and prevention of reproductive losses, as well as improve the quality of life of women. As a result of the analysis, the process of step-by-step diagnosis of pathology was described, the shortcomings of follicle-stimulating hormone, which is considered the main marker in assessing ovarian function, were identified and listed. The advantages of anti-mullerian hormone in the early detection of ovarian failure were also considered.
References
1.Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B va boshq. ESHRE guideline: Management of women with premature ovarian insufficiency. Hum Reprod, 2016; 31(5): 926–937. doi: 10.1093/humrep/dew027
2.Табеева Г.И., Шамилова Н.Н., Жахур Н.А., Позднякова А.А., Марченко Л.А. Преждевременная недостаточность яичников – загадка XXI века. Акушерство и гинекология, 2013; (12): 16–21.
3.Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: A systematic review. Reproductive Biomed Online, 2019; 39(3): 467–476. doi: 10.1016/j.rbmo.2019.04.019
4.Царегородцева М.В., Новикова Я.С., Подолян О.Ф. Преждевременная недостаточность яичников: новые возможности терапии. Климактерий, 2016; (3): 26–31.
5.Torrealday S, Kodaman P, Pal L. Premature ovarian insufficiency – an update on recent advances in understanding and management. F1000Res, 2017; 6:2069. doi: 10.12688/f1000research.11948.1
6.Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016; 19(2): 109–150. doi: 10.3109/13697137.2015.1129166
7.Коваленко И.И., Данусевич И.Н., Наделяева Я.Г., Лазарева Л.М., Аталян А.В., Сутурина Л.В. Характеристика пациенток с преждевременной овариальной недостаточностью по данным госпитального регистра. Международный журнал прикладных и фундаментальных исследований, 2017; (11-1): 53–56.
8.Cox L, Liu JH. Primary ovarian insufficiency: An update. Int J Womens Health, 2014; (6): 235–243. doi: 10.2147/IJWH.S37636
9.Komorowska B. Autoimmune premature ovarian failure. Prz Menopauzalny, 2016; 15(4): 210–214. doi: 10.5114/pm.2016.65666
10.Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny, 2017; 16(2): 47–50. doi: 10.5114/pm.2017.68591
11.
Vincent A, Farrell E. Premature menopause. In: Dvornyk V (ed.). Current topics in menopause. Sharjah: Bentham Science; 2013: 414–441. doi: 10.2174/97816080545341130101
12.Bilgin EM, Kovanci E. Genetics of premature ovarian failure. Curr Opin Obstet Gynecol, 2015; 27(3): 167–174. doi: 10.1097/GCO.0000000000000177
13.Pastore LM, Johnson J. The FMR1 gene, infertility, and reproductive decision-making: A review. Front Genet, 2014; (5): 195. doi: 10.3389/fgene.2014.00195
14.Maclaran K, Nick P. Current concepts in premature ovarian insufficiency. Womens Health (Lond), 2015; 11(2): 169–182. doi: 10.2217/whe.14.82
15.Hudson MM. Reproductive outcomes for survivors of childhood cancer. Obstet Gynecol, 2010; 116(5): 1171–1183. doi: 10.1097/AOG.0b013e3181f87c4b
16.Nguyen HH, Milat F, Vincent A. Premature ovarian insufficiency in general practice: Meeting the needs of women. Aust Fam Physician, 2017; 46(6): 360–366.
17.Петров И.А., Тихоновская О.А., Куприянова И.И., Окороков А.О., Логвинов С.В., Петрова М.С. va boshq. Механизмы вторичной недостаточности яичников при операциях на органах малого таза (экспериментальное исследование). Акушерство, гинекология и репродукция, 2015; 9(4): 6–17. doi: 10.17749/2070-4968.2015.9.4.006-017
18.Соснова Е.А. Эмболизация маточных артерий при миоме матки у пациенток репродуктивного возраста и её роль в формировании аутоиммунного оофорита. Архив акушерства и гинекологии им. В.Ф. Снегирева, 2016; 3(2): 81–87. doi: 10.18821/2313-8726-2016-3-2-81-87
19.Atabekoglu C, Taskin S, Kahraman K, Gemici A, Taskin EA, Ozmen B, va boshq. The effect of total abdominal hysterectomy on serum anti-Müllerian hormone levels: A pilot study. Climacteric, 2012; 15(4): 393–397. doi: 10.3109/13697137.2011.642426
20.Fenton A, Panay N. Does routine gynecological surgery contribute to an early menopause? Climacteric, 2015; 15(1): 1–2. doi: 10.3109/13697137.2012.647623
21.Muzii L, Di Tucci C, Di Feliciantonio M, Galati G, Di Donato V, Mussela A, va boshq. Antimüllerian hormone is reduced in the presence of ovarian endometriomas: A systematic review and meta-analysis. Fertil Steril, 2018; 110(5): 932–940.e1. doi: 10.1016/j.fertnstert.2018.06.025.
